Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 1845 participants.

Also called NCT01858077

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,845 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01858077
Other papers using this trial's data
  • Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2022-03-18 DOI, PubMed 34483094, PMC9743247 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01858077. Randomized; single masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2017-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial
Acronym
AIDA
Intervention (Device)
ABSORB BVS™
Intervention (Device)
XIENCE™
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (class: other)

Record details

Record id
cardio:ct-nct01858077
Content hash
b91bc02f04af0adccc169193a57197ad18539e59ed9332dfa2587e3f1ef0da18